huMNC2 CAR22
Alternative Names: huMNC2-CAR22; MUC1*-CAR-1XXLatest Information Update: 31 Jan 2023
At a glance
- Originator Minerva Biotechnologies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Solid tumours